Leerink Partners downgraded shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Free Report) from an outperform rating to a hold rating in a research note released on Wednesday, MarketBeat Ratings reports. Leerink Partners currently has $40.00 price target on the stock, up from their previous price target of $36.00.
A number of other equities analysts also recently commented on CNTA. Stephens downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Truist Financial boosted their target price on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Wolfe Research lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a report on Tuesday. Chardan Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd. Finally, TD Cowen reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 14th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $40.00.
View Our Latest Analysis on CNTA
Centessa Pharmaceuticals Price Performance
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.10). On average, analysts anticipate that Centessa Pharmaceuticals will post -1.6 EPS for the current year.
Insider Activity at Centessa Pharmaceuticals
In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 41,076 shares of the stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the completion of the sale, the insider owned 62,085 shares of the company’s stock, valued at $1,870,000.20. This trade represents a 39.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gregory M. Weinhoff sold 73,196 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the sale, the insider owned 65,925 shares in the company, valued at $1,735,805.25. This represents a 52.61% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 349,073 shares of company stock worth $9,429,412. 7.09% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Centessa Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in CNTA. American Century Companies Inc. increased its position in shares of Centessa Pharmaceuticals by 3.5% during the second quarter. American Century Companies Inc. now owns 1,130,708 shares of the company’s stock worth $14,858,000 after acquiring an additional 37,954 shares during the last quarter. Royce & Associates LP purchased a new position in Centessa Pharmaceuticals in the third quarter valued at about $5,999,000. Eagle Health Investments LP acquired a new stake in Centessa Pharmaceuticals during the 3rd quarter valued at approximately $2,500,000. Foresite Capital Management VI LLC grew its stake in Centessa Pharmaceuticals by 4.8% during the 3rd quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company’s stock valued at $31,865,000 after purchasing an additional 60,640 shares in the last quarter. Finally, Federated Hermes Inc. purchased a new stake in Centessa Pharmaceuticals during the 3rd quarter worth approximately $42,429,000. 82.01% of the stock is owned by institutional investors and hedge funds.
Centessa Pharmaceuticals News Summary
Here are the key news stories impacting Centessa Pharmaceuticals this week:
- Positive Sentiment: Unusually large purchase of call options — shows bullish speculative interest and potential short-term demand from options traders, which can support the equity even as analysts trim ratings. Investors Purchase High Volume of Centessa Pharmaceuticals Call Options
- Neutral Sentiment: High overall options activity flagged — elevated options volume was reported, but the report does not fully clarify position directions (mix of puts/calls), so the net impact is uncertain. Centessa Pharmaceuticals Target of Unusually High Options Trading
- Negative Sentiment: Guggenheim downgraded CNTA from “buy” to “hold” — a notable sell-side cut from a sizable shop that reduces buy-side conviction and can pressure the stock. Guggenheim downgrades Centessa Pharmaceuticals plc – Depositary Receipt (CNTA)
- Negative Sentiment: Leerink Partners lowered its rating to “hold” — another research downgrade that contributes to negative analyst sentiment. Centessa Pharmaceuticals (NASDAQ:CNTA) Rating Lowered to “Hold” at Leerink Partners
- Negative Sentiment: Stephens cut CNTA to “hold” — adds to a cluster of downgrades from independent research shops. Centessa Pharmaceuticals (NASDAQ:CNTA) Cut to Hold at Stephens
- Negative Sentiment: Multiple other firms (Wolfe Research, Needham, B. Riley and Lifesci Capital) trimmed ratings or moved from “strong-buy” to “hold” — broad-based analyst downgrades increase selling pressure and reduce near-term upside expectations. Wolfe Research Downgrades Centessa Pharmaceuticals to Hold Needham & Company LLC Lowers Rating B. Riley / Lifesci coverage notes
Centessa Pharmaceuticals Company Profile
Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.
Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.
Further Reading
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
